PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra
Stephen J. Chapman
Published online: 1 Mar 2018. DOI: https://doi.org/10.16889/isomerdesign-5

1H NMR spectra of 43 alleged psychedelic tryptamines (2-(1H-indol-3-yl)ethan-1-amines) and benzofuran analogues (2-(1-benzofuran-3-yl)ethan-1-amines) from grey-market internet vendors across North America and Europe were acquired and compared. Tryptamines having mono- or di- alkyl, cyclopropyl, or allyl amine substituents and/or substitution of the indole/benzofuran ring by acetyloxy, hydroxy, methoxy, or methyl groups were analysed. 1H NMR spectra for some of these compounds have not been previously reported to my knowledge. The spectrum of each analyte is consistent with the compound as labelled and sold. None of the analytes was found to be unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.

PeakAL: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra
Stephen J. Chapman and Arabo A. Avanes
Published online: 1 Aug 2015. DOI: https://doi.org/10.16889/isomerdesign-1

1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para-substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.

1H and 13C NMR spectra of N6-allyl-6-norlysergic acid diethylamide (AL-LAD)
Darcy C. Burns, Timothy E. Burrow and Stephen J. Chapman
Published online: 15 Jul 2016. DOI: https://doi.org/10.16889/isomerdesign-3

First reported (online early view): 6 Jun 2016 in:

S.D. Brandt, P.V. Kavanagh, F. Westphal, S.P. Elliott, J. Wallach, T. Colestock, T.E. Burrow, S.J. Chapman, A. Stratford, D.E. Nichols, A.L. Halberstadt. Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2′S,4′S)-lysergic acid 2,4-dimethylazetidide (LSZ). Drug Test. Analysis 2017, 9 (1), 38–50 https://doi.org/10.1002/dta.1985

1H and 13C NMR spectra of (2′S,4′S)-lysergic acid 2,4-dimethylazetidide (LSZ)
Darcy C. Burns, Timothy E. Burrow and Stephen J. Chapman
Published online: 15 Jul 2016. DOI: https://doi.org/10.16889/isomerdesign-4

First reported (online early view): 6 Jun 2016 in:

S.D. Brandt, P.V. Kavanagh, F. Westphal, S.P. Elliott, J. Wallach, T. Colestock, T.E. Burrow, S.J. Chapman, A. Stratford, D.E. Nichols, A.L. Halberstadt. Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2′S,4′S)-lysergic acid 2,4-dimethylazetidide (LSZ). Drug Test. Analysis 2017, 9 (1), 38–50 https://doi.org/10.1002/dta.1985

The Controlled Drugs and Substances Act: Schedules and Structures
Stephen J. Chapman
Published online: 1 Feb 2015. DOI: https://doi.org/10.16889/isomerdesign-2

From acetone to ketamine, LSD to zolpidem, 385 drugs, chemicals, plants and natural products are charted and indexed, including over 350 structural diagrams. Full coverage of Schedules I through VIII of the Controlled Drugs and Substances Act. Includes natural and synthetic opioids and other analgesics, benzodiazepines, barbiturates, amphetamines and other stimulants, psychedelic and entactogenic drugs, anabolic steroids and precursors.